Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Liabilities and Shareholders Equity: 2019-2024

Historic Liabilities and Shareholders Equity for BridgeBio Pharma (BBIO) over the last 6 years, with Dec 2024 value amounting to $919.3 million.

  • BridgeBio Pharma's Liabilities and Shareholders Equity rose 50.12% to $998.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.9 billion, marking a year-over-year increase of 35.88%. This contributed to the annual value of $919.3 million for FY2024, which is 68.26% up from last year.
  • According to the latest figures from FY2024, BridgeBio Pharma's Liabilities and Shareholders Equity is $919.3 million, which was up 68.26% from $546.4 million recorded in FY2023.
  • BridgeBio Pharma's 5-year Liabilities and Shareholders Equity high stood at $1.0 billion for FY2021, and its period low was $546.4 million during FY2023.
  • Moreover, its 3-year median value for Liabilities and Shareholders Equity was $623.0 million (2022), whereas its average is $696.3 million.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first tumbled by 38.48% in 2022, then skyrocketed by 68.26% in 2024.
  • Over the past 5 years, BridgeBio Pharma's Liabilities and Shareholders Equity (Yearly) stood at $703.6 million in 2020, then surged by 43.95% to $1.0 billion in 2021, then crashed by 38.48% to $623.0 million in 2022, then decreased by 12.30% to $546.4 million in 2023, then skyrocketed by 68.26% to $919.3 million in 2024.